Mr. Jim Breslin:

This is the process by which we determine the vulnerability and impact. The criticality assessment exercise looked at therapeutic areas where there would be high impact if we did not have the drug. It also looked at the vulnerability of the drug, including its relationship to the UK. It then interrogated with the manufacturers those products to verify, and not simply be assured on, the extent of the preparations in place. Resulting from this we have very much whittled down the type of risk we face. Without being categoric, our biggest risk in the initial period is with regard to short shelf life drugs. If we have disruption of a drug where we have eight to ten weeks of supply already buffered in Ireland we can replenish over that period as we go along but if we have a short shelf life drug and there is disruption in the UK it is of concern to us. Most of the very short shelf life drugs do not come over the land bridge but some come directly from the UK to Ireland. They are manufactured in the UK and come across the Irish Sea. We have worked with the suppliers of these particular drugs to assess the capacity we have in the country in the first instance. If we had no ability to-----